Sort
82,697 grants matching “vaccine development”
UAB-MISS MACS/WIHS Combined Cohort Study
$2,924,365Mirjam-Colette Kempf · University Of Alabama At Birmingham · U01 · FY2025 · HL
SPORE in Prostate Cancer
$2,924,249Sloan-Kettering Institute For Cancer Res · P50 · FY2004 · CA
Mucosal Immunity, Vaccines and Microbiota Interplay in Humans and Animal
$2,924,203Marcelo B. Sztein · University Of Maryland Baltimore · U19 · FY2010 · AI
Radiation Therapy Oncology Group
$2,923,989Walter John Curran · American College Of Radiology · U10 · FY2011 · CA
Optimizing malaria transmission-blocking vaccines with improved platforms
$2,921,105Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Role of norovirus capsid dynamics in adaptive immune evasion
$2,920,356Thomas J Smith · University Of Texas Med Br Galveston · R01 · FY2025 · AI
UCSD Department of Medicine HIV/AIDS Clinical Trials Unit
$2,919,144Constance Ann Benson · University Of California, San Diego · UM1 · FY2012 · AI
Tuberculosis Research Unit
$2,918,841W. Henry Boom · Case Western Reserve University · N01 · FY2011 · AI
UAB-MISS MACS/WIHS Combined Cohort Study
$2,918,360Mirjam-Colette Kempf · University Of Alabama At Birmingham · U01 · FY2023 · HL
DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.
$2,916,500Ali I. Fattom · Bluewillow Biologics, Inc. · N44 · FY2020 · AI
Shared Resource Management
$2,916,130M. Celeste Simon · University Of Pennsylvania · P30 · FY2021 · CA
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines
$2,915,139Harriet L Robinson · Geovax, Inc. · U19 · FY2007 · AI
Cervical cancer and human papillomavirus (HPV) infection
$2,915,100Mark Schiffman · Division Of Cancer Epidemiology And Genetics · Z01 · FY2008 · CA
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders
$2,915,077Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2010 · HL
MIDAS Center for Communicable Disease Dynamics
$2,914,212Marc Lipsitch · Harvard School Of Public Health · U54 · FY2011 · GM
UAB-MISS MACS/WIHS Combined Cohort Study
$2,913,464Mirjam-Colette Kempf · University Of Alabama At Birmingham · U01 · FY2021 · HL
Project 5: mRNA and mRNA-launched nanoparticle vaccines
$2,913,088Neil King · University Of Washington · U19 · FY2024 · AI
DNA/MWA Immunogens, Cross-clade Immune Responses
$2,912,750Emory University · P01 · FY2002 · AI
Project 4 - Inhibitors of Flavivirus Replication
$2,911,345Margo A Brinton · Emory University · U19 · FY2022 · AI
Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax
$2,910,854Kenneth Mark Coggeshall · Oklahoma Medical Research Foundation · U19 · FY2014 · AI
Role of antigen-specific T cell responses in the control of TB
$2,910,650Henry M Blumberg · Emory University · U19 · FY2016 · AI
Bone Marrow Transplantation in Human Disease
$2,910,583Richard J Jones · Johns Hopkins University · P01 · FY2008 · CA
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses
$2,910,308Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes
$2,909,196Abraham Pinter · Rbhs-New Jersey Medical School · P01 · FY2013 · AI
Vaccination and infection: indicators of immunological health and responsiveness
$2,908,842Mark M Davis · Stanford University · U19 · FY2013 · AI